Biotech Values

[iwfal]

XOMA -

SERVIER believes gevokizumab has the potential to treat a wide range of indications beyond Behcet's uveitis, non-infectious uveitis, and cardiovascular diseases,"

FWIW NVS has potent (but sparse) CIMT-type data for their IL-1 blocker in cardiac (I believe it was in their R&D day slides). Much bigger effect than I have ever seen before for any treatment paradigm and IVUS (with which I am more familiar). Perhaps an artifact of non-cardiac arteries - but seems improbable.